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service as the item being valued. We examined whether
DC CV questions lead to hypothetical bias for this good,
and we tested whether “definitely sure” hypothetical yes
responses, as identified in a follow-up question, corre-
spond to real yes responses. METHODS: 172 subjects
with asthma were recruited from 10 Kentucky commu-
nity pharmacies. Subjects received either a DC CV ques-
tion or were given the opportunity to actually purchase
the service. Three different prices were used: $15, $40,
and $80. RESULTS: In the hypothetical group 38% of
subjects stated they would purchase the good at the given
price, but only 12% of subjects in the real group pur-
chased the good (p  0.000). We cannot, however, reject
the null hypothesis that “definitely sure” hypothetical yes
responses correspond to real yes responses. CONCLU-
SIONS: The DC CV method overestimates WTP in the
HCS, but it may be possible to correct for this by sorting
out “definitely sure” yes responses.
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OBJECTIVE: The primary objective was to evaluate the
relationship between willingness to pay (WTP), quality of
life (QOL), and disease severity measures in asthma pa-
tients. The hypothesis studied was that asthma patients
with more severe disease, as measured objectively via
forced expiratory volume percent predicted (FEV1%),
are willing to pay more for a hypothetical cure from
asthma than those with less severe disease. METHODS:
One-hundred asthmatic patients were recruited from
community pharmacies in Kentucky for 30 minute face-
to-face interviews. Spirometry was used to assess ob-
jective disease severity while a multiple choice question
assessed subjective disease severity. The Short Form 36
(SF-36) and Asthma Technology of Patient Experience
(Asthma TyPE) measured QOL. WTP was obtained via a
dichotomous choice contingent valuation question. RE-
SULTS: WTP was significantly related to both objective
disease severity (p  0.02) and subjectively assessed dis-
ease severity (p  0.01). For objective disease severity the
mean monthly WTP was $90 for mild asthma, $131 for
moderate asthma and $331 for severe asthma; and for
subjective disease severity the mean monthly WTP was
$48 for mild asthma, $166 for moderate asthma and
$241 for severe asthma. A majority of the QOL measures
were correlated with WTP. CONCLUSIONS: The results
suggest that the WTP for a cure from asthma is related to
both objective and subjective disease severity.
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OBJECTIVES: Cilomilast is a potent and selective phos-
phodiesterase type 4 (PDE4) inhibitor currently under
development for the treatment of chronic obstructive pul-
monary disease (COPD) and asthma. METHODS: COPD-
related health care resource utilization including physi-
cian visits, emergency room visits, hospitalizations and
medication use were prospectively collected in a 6 month
randomized, double-blind, placebo controlled, parallel
group study of patients on cilomilast, 15 mg bid (n 
431) versus patients on placebo (n  216). Methods of
analysis included descriptive statistics, Kaplan-Meier esti-
mates and Poisson regression. RESULTS: In the year
prior to the study, COPD-related health care resource
utilization was comparable between patients eventually
randomized to cilomilast and those randomized to pla-
cebo; the majority of all patients had no or one emer-
gency room visit or hospitalziation. During the entire 24-
week study period, the cumulative incidence of health
care utilization was significantly lower in the cilomilast
group than the placebo group in terms of all utilization
(11.0% vs. 21.1%, p  0.004); including physician visits
(11.9% vs. 23.1%, p  0.002), emergency room visits
(0.6% vs. 4.5%, p  0.004) and hospitalization (0.5%
vs. 3.4%, p  0.021). The relative utilization rates per
patient-month of follow-up for each of the utilization
types were lower in the cilomilast group than in the pla-
cebo group. Treatment with cilomilast resulted in reduc-
tion of all utilization by 51% (C.I.: 31%, 65%), physi-
cian visits by 41% (C.I.: 15%, 59%). ER visits and
hospitalizations were also significantly reduced. CON-
CLUSIONS: In this study, cilomilast was associated with
significantly less COPD-related health care resource utili-
zation, including hospitalizations, emergency room visits
and physician visits than placebo.
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OBJECTIVES: Asthma is a common medical condition
that is increasing in prevalence. The purpose of this study
was to examine costs associated with treating asthma pa-
tients within a managed care organization (MCO).
METHODS: Data for this study were obtained from a
managed care organization located in the Western region
of the US. Patients were eligible for inclusion if they met
one of the following criteria: a diagnosis of asthma (ICD-
9 code of 493.xx); two or more prescriptions used to
control asthma (e.g., inhaled corticosteroid, leukotriene
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modifier, mast cell stabilizer, xanthine derivative, or a
long acting beta agonist); or one prescription for an
asthma controller and one or more prescriptions for a
short acting beta-agonist. Patients also had to be full year
members of the MCO. Patients with a diagnosis of
chronic obstructive lung disease were excluded. RE-
SULTS: A total of 351,140 persons were continuously
enrolled in the MCO during 1999. A total of 8,051 per-
sons were identified as having asthma (2.3% of the MCO
enrollees), with 43% being male. Persons under 18 years
of age comprised 28.8% of persons with asthma. Median
pharmacy costs were $472, median medical costs were
$483, and median total health care costs were $1199 for
this population. CONCLUSIONS: Asthma appears to af-
fect a significant number of enrollees within this MCO,
with persons less than 18 years of age representing al-
most 29% of the treated patients. Health care costs in
persons with asthma appears to be substantial.
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OBJECTIVES: The objective of this study is to determine
the factors that influence satisfaction with non-sedating
antihistamines (NSA) among people who suffer from al-
lergies/hay fever. METHODS: An online survey was con-
ducted in September, 2000 on respondents who had been
told by a health care professional that they suffer from al-
lergies/hay fever and were recently (within 12 months)
prescribed one of three NSAs to relieve their symptoms.
The sample was weighted to ensure the generalizability of
the results. Satisfaction was measured according to the
medication’s ability to relieve side effects and control
symptoms from allergies/hay fever. A total of 4,081 re-
spondents were included in the analysis. RESULTS: (1)
The mean satisfaction score for the first time users (de-
fined as never having taken any medication for allergies/
hay fever) was higher than those who had used some
medication in the past (p  .01) (2) Of the respondents
who had a specific choice of medication in mind, those
who received their first choice medication had a higher
satisfaction score than those who did not (p  .01). (3)
The respondents who discussed their medication jointly
with their physician had a higher satisfaction score than
those whose doctor chose their medication for them (p 
.01). (4) Respondents who were not taking any over-the-
counter (OTC) medications reported higher satisfaction
scores than those who supplemented their NSA with
over-the-counter medications (p  .01). (5) Finally, re-
spondents who had never requested a prescription after
seeing an advertisement for any medication had a higher
satisfaction score than those who did. (p  .01) CON-
CLUSIONS: The data provides evidence to suggest that
past knowledge or experience with NSAs, patient prefer-
ence, and patient involvement in the treatment decision-
making process all play a role in determining satisfaction
with NSAs. Furthermore, both over-the-counter medica-
tion usage and direct-to-consumer advertising are likely
to influence how satisfied people are with their NSA.
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INTRODUCTION: Despite the high prevalence, mor-
bidity and mortality of COPD, remarkably little is
known about its impact on health care costs and utiliza-
tion of services. Information about health care utilization
and costs among patients with Chronic Obstructive Pul-
monary Disease (COPD) is needed to improve care and
for appropriate allocation of resources. OBJECTIVE:
The purpose of this study was to quantify the burden of
illness in Italy, in terms of both medical consumption and
lost productivity associated with COPD. METHODS:
Design: In 1998 an epidemiological study was conducted
in Italy. Retrospectively, from a community perspective,
we quantified COPD’s costs related both with health care
consumption and lost of productivity and/or school days.
Main Outcomes Measures: The main goal of the present
study was to evaluate economic outcomes in a cohort of
355,000 patients with current diagnosis of COPD. RE-
SULTS: As reported in previous studies, prevalence rate
for COPD in Italy is about 4,6% (2,637,000 subjects).
Among all COPD patients, 42,5% suffers from mild dis-
ease while 56,7% is affected by moderate-severe COPD,
on the basis of Flow Expiratory Value (FEV1) % of pre-
dicted criteria. The total cost of COPD we have quoted is
the sum of direct and indirect costs: it is worth US$18 bil-
lion, equal to US$6,843 average/patient/year. We have
not included intangible costs because they cannot be
quantified correctly as yet. CONCLUSIONS: COPD is
associated with significant both direct and indirect costs.
Previous studies reported that prevalence figures for
COPD based on recorded diagnoses are underestimated.
Notwithstanding, data from our study suggest that when
patients seek medical advice they were correctly diag-
nosed and treated. Education of patients will allow them
to take control of their disease and of costs related to
COPD.
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OBJECTIVE: Salmeterol, a long acting beta-2 agonist,
improves lung function and symptom control with twice
daily dosing in moderate-to-severe asthmatics. This in-
